Survivin is a unique member of the inhibitor of apoptosis protein family, and its expression is regulated by p53. Recent identification of several functionally divergent survivin variants augments the complexity of survivin action as well as its regulation. Here we report that survivin-2B (retaining a part of intron 2 as a cryptic exon) is positively regulated by p53, and its overexpression plays a role in sensitizing leukemia cells to chemotherapeutic drug doxorubicin. Doxorubicin treatment activated p53, downregulated survivin and survivin-DEx3 but upregulated survivin-2B in EU-3, an acute lymphocytic leukemia (ALL) cell line with wild-type (wt)-p53 phenotype. In contrast, doxorubicin treatment failed to induce these alterations in EU-6 cells, a mutant-p53 ALL cell line. To specify the role of wt-p53 in regulating survivin and its variants, a temperature-sensitive p53 mutant plasmid p53-143 was transfected into EU-4, a p53-null ALL cell line, to establish a subline EU-4/p53-143. When EU-4/p53-143 cell culture was shifted from 37.5 C to the wt-p53-permissive temperature (32.5 C), the expression of survivin and survivin-DEx3 was decreased whereas survivin-2B expression was increased, confirming the distinct regulatory effect of p53 on survivin and its variants. To clarify the role of survivin-2B in the process of apoptosis, survivin-2B cDNA was cloned into pcDNA3HA vector and transfected into EU-4 cells. Enforced expression of survivin-2B in EU-4 cells inhibited cell growth and sensitized these cells to doxorubicin-induced apoptosis. These results suggest that survivin-2B variant is a proapoptotic factor and its expression is upregulated by p53.
Introduction
Survivin, a unique member of the inhibitor of apoptosis protein (IAP) family, plays an important role in regulating both apoptosis and cell division (Li et al., 1998 (Li et al., , 1999 . It is overexpressed in almost all types of human malignancies but is undetectable in most normal differentiated tissues (Li et al., 1999) . Overexpression of survivin is associated with a more aggressive disease, drug resistance, increased risk of recurrence and poor survival in cancer patients (Monzo et al., 1999; Swana et al., 1999; Adida et al., 2000; Kuwabara et al., 2001) . Accordingly, inhibiting the expression of survivin can reduce tumor growth potential and result in an increased sensitivity to anticancer agents (Tu et al., 2003; Pennati et al., 2004) .
In addition to the orthodox survivin, several alternatively spliced variants of survivin have been identified: survivin-DEx3 (lacking exon 3) retains the antiapoptotic function; survivin-2B (retaining a part of intron 2 as a cryptic exon) exhibits a marked reduction in antiapoptotic potential; and survivin-3B (retaining a part of intron 3), whose function remains to be determined (Mahotka et al., 1999; Badran et al., 2004) . These functionally divergent survivin variants are often simultaneously expressed in cancer cells along with the orthodox survivin (Hirohashi et al., 2002) , implying that these variants may be involved in the fine-tuning of survivin action.
Previous studies have demonstrated that the expression of survivin is tightly regulated, and the tumor suppressor p53 negatively regulates survivin expression (Hoffman et al., 2002; Mirza et al., 2002; Zhou et al. 2002) . However, the regulation of survivin variants has not been characterized. In order to evaluate whether p53 plays a role in regulating survivin variants, we examined the expression of survivin variants as well as survivin in acute lymphocytic leukemia (ALL) cells, in which p53 was either activated by treatment with DNA-damaging agent doxorubicin or induced by subjecting a temperature-sensitive mutant p53 to temperature shift. We found that expression of antiapoptotic survivin-DEx3 was downregulated by p53 just as survivin was, whereas expression of survivin-2B was upregulated by p53. These interesting findings prompted us to explore the role of survivin-2B in regulating cell growth and apoptosis. Our results showed that enforced expression of survivin-2B in ALL cells inhibited cell growth and sensitized leukemia cells to doxorubicin-induced apoptosis. These findings demonstrated for the first time that survivin-2B not only loses the antiapoptotic function but rather acts as a proapoptotic factor. Moreover, our studies indicated that the differential modulation of survivin and survivin variants might represent a novel mechanism for the effect of p53 on induction of apoptosis.
Results
Upregulation of survivin-2B in wt-p53 þ ALL cells in response to doxorubicin
We previously reported that doxorubicin treatment of wild-type (wt)-p53 þ EU-3 ALL cells resulted in accumulation of p53, downregulation of survivin expression and induction of apoptosis (Zhou et al., 2002) . We extended our studies to evaluate the expression of survivin variants in this cell line. As shown in Figure 1a , wt-p53 accumulated in EU-3 cells after treatment with doxorubicin within 1-5 h, accompanied by downregulation of mRNAs for survivin and survivinDEx3, but upregulation of survivin-2B mRNA expression ( Figure 1b) . In contrast, downregulation of survivin-DEx3 as well as survivin and upregulation of survivin-2B were not observed in mut-p53 EU-6 cells after doxorubicin treatment. Consistent with these observations, doxorubicin treatment resulted in significant apoptosis in EU-3 cells but not in EU-6 cells (Figure 1c ), suggesting that in addition to downregulation of survivin, differential modulation of survivin variants may also be required for p53-mediated apoptosis induced by doxorubicin.
Upregulation of survivin-2B by p53 induction
To evaluate the role of p53 in regulating the expression of survivin variants, a temperature-sensitive mutant p53 plasmid (p53-143) was stably transfected into EU-4, a p53-null ALL cell line. The p53 protein encoded by this plasmid exists in a mutant conformation at 37.5 C, but changes to a wt conformation at 32.5 C. As shown in Figure 2a and b, when EU-4 cells transfected with this plasmid (EU-4/p53-143) were shifted from 37.5 to 32.5 C, wt-p53 function was activated, as demonstrated by induction of the promoter luciferase activity of p21 gene and protein expression of MDM2 as well as p21, which are the p53 targets. Accompanying p53 activation, survivin and survivin-DEx3 were downregulated, whereas survivin-2B was upregulated (Figure 2c and d) . The expression of survivin and its variants remained unchanged in EU-4 cells transfected with a control plasmid (CMV-neo) at 32.5 C (data not shown). These results confirmed the regulatory effect of p53 on survivin variants.
Inhibition of cell growth by overexpression of survivin-2B
Previous studies indicated that antiapoptotic genes are usually downregulated by p53, while proapoptotic genes are often upregulated by p53 (Fridman and Lowe, 2003) . The upregulation of survivin-2B by p53 prompts us to explore the role of survivin-2B in the processes of apoptosis. After survivin-2B cDNA was cloned into pcDNA3HA vector, we stably transfected this plasmid into the p53-null EU-4 cells. Transfection of the empty vector served as a control. As shown in Figure 3a , survivin-2B was successfully transfected in EU-4 cells as detected by anti-HA antibody. Moreover, overexpression of survivin-2B mRNA was detected as shown in Figure 3b , which showed an approximately fourfold increase of survivin-2B expression in survivin-2B-trans- 
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Regulation of survivin-2B and its function N Zhu et al fected cells as compared with parental EU-4 and control transfectant. Forced overexpression of survivin-2B significantly decreased cell growth as shown in Figure 3c , in which the growth rate of EU-4/survivin-2B was only half that of EU-4/neo cells after 4 or 6 days of culture. At this point, cell-doubling times were 38 and 20 h for EU-4/survivin-2B and EU-/neo cells, respectively. Additional five EU-4/survivin-2B clones were tested and expressed similar slower growth rates as compared to EU-4/neo cells (data not shown).
Sensitization to doxorubicin-induced apoptosis by survivin-2B overexpression
We next evaluated the effect of survivin-2B overexpression on cellular sensitivity to doxorubicin, a frequently used chemotherapeutic drug for leukemia and other cancers. Results from our previous study indicated that parental EU-4 cells that express high levels of survivin and low levels of survivin-2B were resistant to doxorubicin (Zhou et al., 2002) . In the present study, we found that overexpression of survivin-2B sensitized these cells to doxorubicin. As shown in Figure 4a , a significant difference was noted in mean cell survival after 48 h treatment between EU-4/survivin-2B and EU-4/neo cells at doxorubicin concentrations of 1 mM and greater (Po0.05, t-test). Consistent with these observations, significant activation of caspase-3 and cleavage of its substrate PARP were detected at 24 h after doxorubicin treatment in EU-4/survivin-2B cells, whereas cleavage of these two proteins was not observed at this time point post-doxorubicin in EU-4/neo control cells (Figure 4b ). Furthermore, annexin-V expression analysed by flow cytometry indicated that more cells underwent apoptosis in EU-4/survivin-2B than did control cells in response to doxorubicin treatment. As seen in Figure 4c , 32% of EU-4/survivin-2B cells underwent apoptosis compared with 16% of EU-4/neo control cells following treatment with 1.5 mM doxorubicin for 24 h.
Discussion
Due to its unique expression in tumor cells and antiapoptotic function, survivin has emerged as a promising C as fold-changes compared to that at 37.5 C (nonpermissive temperature). Actin was used as internal control Regulation of survivin-2B and its function N Zhu et al target for cancer therapy. Recent studies have demonstrated that in addition to the orthodox survivin, several survivin variants are often expressed in cancer cells with survivin/survivin-2B/survivin-DEx3 ratio of 5-7 : 1 : 1 (Li, 2003) . Among survivin variants, survivin-2B is notable, since several lines of evidence indicate that its function may be different from that of survivin and other variants: (1) the antiapoptotic potential of survivin-2B was significantly diminished compared with that of survivin (Mahotka et al., 1999 (Mahotka et al., , 2002a ; (2) a reverse correlation between the expression level of survivin-2B and tumor progression has been observed, implying that survivin-2B is a favorable index (Krieg et al., 2002; Mahotka et al., 2002b) ; (3) an opposite alteration tendency between survivin-2B and survivin expression was noticed when cancer cells are induced toward apoptosis (Islam et al., 2000) . Thus, survivin-2B is believed to be a naturally occurring antagonist of survivin (Islam et al., 2000) .
In the present study, we successfully transfected EU-4 cells with a plasmid containing survivin-2B cDNA, which resulted in enhanced expression of survivin-2B in EU-4 cells. In survivin-2B-overexpresing EU-4 cells, we witnessed inhibition of cell proliferation and increased apoptosis induced by doxorubicin. These results clearly demonstrated that survivin-2B shows a gain of proapoptotic function, not merely loss of antiapoptotic function. Although the precise mechanism for survivin-2B in promoting apoptosis is not well defined, previous studies have suggested that survivin-2B exerts its proapoptotic effect by interfering with survivin function through a dominant-negative mechanism (Mahotka et al., 1999; Islam et al., 2000) . Inhibition of EU-4 cell growth and sensitization of these cells to doxorubicin by enforced overexpression of survivin-2B could be due to inhibition of the antiapoptotic function of survivin or to direct induction of apoptosis through unknown mechanisms.
It has been previously determined that p53 can repress survivin expression, and reduction of survivin expression plays an important role in p53-mediated apoptosis (Mirza et al., 2002; Zhou et al., 2002) . In the present study, we found that proapototic survivin-2B was upregulated by p53, whereas antiapoptotic survivin-DEx3, as well as survivin, was downregulated by p53. In wt-p53 EU-3 cells treated with doxorubicin, these alterations occurred promptly along with p53 activation, much earlier than apoptosis occurred in these cells. Thus, these results suggest that upregulation of survivin-2B may also play a role in p53-mediated apoptosis. However, in our study, we could not measure changes in the net amount of survivin-2B upon p53 induction in a single reverse transcription (RT)-PCR reaction. Whether the relative amount of induced survivin-2B is high enough as a dominant-negative inhibitor to bind to and inhibit survivin and survivin-Ex3, or alternatively survivin-2B induces apoptosis by itself, remains to be further investigated.
Since all the survivin variants are generated from the same survivin pre-mRNA through alternative splicing (Mahotka et al., 1999) , p53 may regulate survivin expression at the mRNA splicing level. Alternative pre-mRNA splicing is a fundamental mechanism for regulating the expression of many eucaryotic genes (Lopez, 1998) , especially the apoptosis-related genes, since many apoptotic regulatory genes (e.g. bcl-x, caspase-2 and caspase-9) encode for alternatively spliced protein variants with opposing functions (Minn et al., 1996; Jiang et al., 1998; Seol and Billiar, 1999) . Indeed, alternative splicing has been shown to be an effective way to regulate apoptotic response (Chalfant et al., 2002; Mercatante et al., 2002) . Interestingly, p53 was found to play a role in regulating mRNA splicing, including the splicing of the apoptotic inducer bax (Maxwell et al., 1999; Moyret-Lalle et al., 2001; Xu and el-Gewely, 2003) . Thus, it is not surprising that p53, a critical tumor suppressor and apoptosis mediator, may differentially regulate the expression of survivin, an important IAP member, through modulating the splicing of survivin pre-mRNA.
In summary, the present study has confirmed a proapoptotic function for survivin-2B and demon- strated that functionally opposite survivin variants are distinctly regulated by p53. Our results reveal a novel mechanism for p53-mediated apoptosis, which involves upregulation of proapoptotic survivin-2B and downregulation of survivin-DEx3 as well as survivin. Selective induction of survivin-2B expression may provide a novel approach to sensitize cancer cells to radiation and chemotherapy.
Materials and methods

Cell lines and treatment
The ALL cell lines EU-3, EU-4 and EU-6 were established in our laboratory from three pediatric ALL patients during relapse. These three lines were chosen in the present study due to their distinct p53 phenotypes: EU-3 expresses wt-p53, EU-6 has a p53 point mutation in position 273, while EU-4 does not express p53 as described previously (Zhou et al., 1995) . These cell lines were cultured in RPMI 1640 medium containing 10% FBS, 2 mmol/l L-glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin at 37 C in 5% CO 2 -in-air. Cells in exponential growth were exposed to doxorubicin treatment.
Plasmids and gene transfection
Expression plasmid pCMV-p53-143 was kindly provided by Dr B Vogelstein (Johns Hopkins University School of Medicine). This plasmid encodes a mutant p53 protein that displays mutant and wt conformation at 37.5 and 32.5 C, respectively (Zhang et al., 1994) . Expression plasmid containing survivin-2B was constructed as follows: The cDNA for the open reading frame of survivin-2B was obtained by RT-PCR using forward primer 5 0 -GGAATTCCATGGGTGCCCC GACGTTG-3 0 and reverse primer 5 0 -GGGGTACCTC GAGCTAAGACATTGCTAAGGGGC-3 0 . The PCR product of survivin-2B cDNA (625 bp) was separated on a 1.5% agarose gel and purified with the GENECLEAN R II Kit (BIO101, Carlsbad, CA, USA). The purified cDNA fragment was digested by EcoRI and XhoI, and cloned into the pcDNA3HA vector in-frame with HA-tag sequence at the EcoRI and XhoI sites. The cDNA sequence of survivin-2B in this expression vector was confirmed by DNA sequencing.
EU-4 cells in exponential growth were either transiently or stably transfected with each expression plasmid by electroporation at 290 V, 950 mF using a Gene Pulser II System (BioRad, Hercules, CA, USA). For stable transfection, the cells were seeded 48 h post-transfection into culture dishes for the selection of G418-resistant colonies. Colonies were grown in methylcellulose medium containing G-418 for 1-2 weeks, and clones were picked and grown in RPMI medium with or C to either 37.5 or 32.5 C for different times. Cell extracts were prepared with 1 Â lysis buffer, and then 20 ml aliquots of the supernatant were mixed with 100 ml of luciferase assay reagent (Promega) and analysed on a Microplate Luminometer (Turner Designs). Luciferase activities were normalized to b-galactosidase activity as an internal control.
RT-PCR
Because antibodies against survivin variants have not been available, we performed RT-PCR to examine the expression of survivin variants. Total RNA was extracted using Ultraspec Reagent (Biotecx Laboratories Inc., Houston, TX, USA). RT-PCR was performed with an Access RT-PCR Kit (Promega Corporation) according to the manufacturer's protocols. To specifically amplify and detect survivin, survivin-DEx3 and survivin-2B respectively, one common forward primer 5 0 -TCAAGGACCACCGCATCTCTAC-3 0 and three different reverse primers were used. The reverse primers for survivin, survivin-DEx3 and survivin-2B were 5 0 -GCACTTTCTTCG CAGTTTCCTC-3 0 , 5 0 -TGGTTTCCTTGGCATGGGG-3 0 and 5 0 -GTGCTGGTATTACAGGCGTAAG-3 0 , respectively. Expected sizes of PCR products for survivin, survivin-DEx3 and survivin-2B were 355, 195 and 221 bp, respectively. For survivin and survivin-DEx3 amplification, 0.2 mg total RNA was used in 50 ml RT-PCR systems and the reaction was carried out as follows: 48 C for 45 min, 94 C for 2 min, 30 cycles of denaturation at 94 C for 15 s, annealing at 57 C for 30 s and extension at 68 C for 1 min. For survivin-2B amplification, 1.0 mg of total RNA was used in the 50 ml RT-PCR systems, 5% (v/v) of DMSO was added to the reaction mixture, and annealing temperature in the 30-cycle amplification was reduced to 54 C. As an internal control, b-actin was amplified by using forward primer 5 0 -GTGGGGCGCC CCAGGCACCA-3 0 and reverse primer 5 0 -GTCCTTAATGT CACGCACGATTTC-3 0 . The PCR products were visualized with ethidium bromide staining under UV light after electrophoresis on a 1.5% agarose gel, and bands were quantitated using Kodak ID image software.
Determination of cell growth
EU-4 cells transfected with survivin-2B gene and control cells (parental EU-4 cells and EU-4 cells transfected with an empty vector) were cultured at a starting concentration of 10 4 /ml. Cells were counted daily using a hemocytometer. Triplet cultures were counted for each time point to determine the growth rate.
Cytotoxicity and apoptosis assays
The cytotoxic effect of doxorubicin on the ALL cell lines was determined by the XTT assay. Briefly, cells were cultured in 96-well microtiter plates with different concentrations of doxorubicin for 44 h. XTT (25 mg/well) was then added and cells were incubated for an additional 4 h. The optical density (OD) of the wells was then read with a microplate reader at a test wavelength of 450 nm and a reference wavelength of 620 nm. Appropriate controls lacking cells were included to determine background absorbance.
An annexin-V assay (Oncogene, San Diego, CA, USA) was used to quantitate apoptosis cells. Briefly, cells with or without treatment were washed once with PBS and stained with FITCannexin-V and PI for 30 min according to the manufacturer's instructions. Stained cells were detected using the FACScan (Becton Dickinson) and analysed using WinList software (Verity Software House Inc.).
Western blot assay
Cells were lysed in a buffer composed of 150 mM NaCl, 50 mM Tris (pH 8.0), 5 mM EDTA, 1% (v/v) Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 20 mg/ml aprotinin and 25 mg/ ml leupeptin for 30 min at 4 C. Equal amounts of protein extracts (10 mg) were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose filters. After blocking with buffer containing 20 mM Tris-HCl (pH 7.5), 500 mM NaCl and 5% non-fat milk for 1 h at room temperature, the filter was incubated with specific antibodies for 3 h at room temperature. After washing, the filter was incubated with horseradish peroxidase-labeled secondary antibody for 1 h. Blots were developed using a chemiluminescent detection system (ECL, Amersham Life Science, Buckinghamshire, England).
